RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
-5.97%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$522M
AUM Growth
+$522M
(-17%)
Cap. Flow
-$70.4M
Cap. Flow
% of AUM
-13.5%
Top 10 Holdings %
Top 10 Hldgs %
27.83%
Holding
119
New
12
Increased
37
Reduced
37
Closed
11
Top Buys
| 1 |
Gilead Sciences
GILD
|
$18.6M |
| 2 |
Medtronic
MDT
|
$15.3M |
| 3 |
Pfizer
PFE
|
$10.8M |
| 4 |
Elevance Health
ELV
|
$8.38M |
| 5 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$5.42M |
Top Sells
| 1 |
SHPG
Shire pic
SHPG
|
$26.6M |
| 2 |
CELG
Celgene Corp
CELG
|
$10.8M |
| 3 |
UnitedHealth
UNH
|
$8.8M |
| 4 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$8.56M |
| 5 |
Merck
MRK
|
$7.65M |
Sector Composition
| 1 | Healthcare | 94.79% |
| 2 | Financials | 1.61% |
| 3 | Technology | 0.16% |
| 4 | Energy | 0.11% |
| 5 | Consumer Discretionary | 0.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
51
Merck
MRK
$210B
| $4.12M | 0.79% |
70,000
-130,000
| -65% | -$7.65M |
|
52
Omnicell
OMCL
$1.51B
| $4.02M | 0.77% |
118,537
| – | – |
|
53
Glaukos
GKOS
$5.42B
| $3.97M | 0.76% |
115,800
+110,700
| +2,171% | +$3.8M |
|
54
Labcorp
LH
$22.8B
| $3.85M | 0.74% |
30,000
| – | – |
|
55
LivaNova
LIVN
$3.09B
| $3.6M | 0.69% |
+80,000
| New | +$3.6M |
|
|
KITE
56
DELISTED
Kite Pharma, Inc.
KITE
| $3.59M | 0.69% |
80,000
-10,000
| -11% | -$448K |
|
57
Esperion Therapeutics
ESPR
$490M
| $3.44M | 0.66% |
275,000
+145,000
| +112% | +$1.82M |
|
|
ELGX
58
DELISTED
Endologix Inc
ELGX
| $3.29M | 0.63% |
575,000
+140,000
| +32% | +$801K |
|
59
Universal Health Services
UHS
$11.6B
| $3.19M | 0.61% |
30,000
| – | – |
|
60
MacroGenics
MGNX
$121M
| $3.17M | 0.61% |
155,000
+15,000
| +11% | +$307K |
|
|
NDRM
61
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
| $3.17M | 0.61% |
142,546
-2,000
| -1% | -$44.4K |
|
62
Coherus Oncology, Inc. Common Stock
CHRS
$146M
| $3.14M | 0.6% |
111,357
-20,000
| -15% | -$563K |
|
63
Rigel Pharmaceuticals
RIGL
$710M
| $3.05M | 0.58% |
1,282,000
-118,000
| -8% | -$281K |
|
64
DaVita
DVA
$9.72B
| $2.89M | 0.55% |
45,000
-10,000
| -18% | -$642K |
|
|
PTLA
65
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $2.71M | 0.52% |
120,805
| – | – |
|
|
TSRO
66
DELISTED
TESARO, Inc.
TSRO
| $2.69M | 0.52% |
20,000
-1,500
| -7% | -$202K |
|
|
KERX
67
DELISTED
Keryx Biopharmaceuticals Inc
KERX
| $2.49M | 0.48% |
425,111
-75,000
| -15% | -$439K |
|
68
FibroGen
FGEN
$48.4M
| $2.23M | 0.43% |
104,000
| – | – |
|
|
ADMS
69
DELISTED
Adamas Pharmaceuticals, Inc.
ADMS
| $2.2M | 0.42% |
130,000
| – | – |
|
|
ICPT
70
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $2.17M | 0.42% |
20,000
+10,000
| +100% | +$1.09M |
|
|
RDUS
71
DELISTED
Radius Health, Inc.
RDUS
| $2.09M | 0.4% |
55,000
-20,000
| -27% | -$761K |
|
72
Perrigo
PRGO
$3.21B
| $2.08M | 0.4% |
25,000
-10,000
| -29% | -$832K |
|
|
WBA
73
DELISTED
Walgreens Boots Alliance
WBA
| $2.07M | 0.4% |
25,000
-40,000
| -62% | -$3.31M |
|
74
Acadia Pharmaceuticals
ACAD
$4.34B
| $2.02M | 0.39% |
70,000
+20,000
| +40% | +$577K |
|
75
Illumina
ILMN
$15.2B
| $1.92M | 0.37% |
+15,000
| New | +$1.92M |
|